D220

DKFZ -Bayer Healthcare Joint Also known as:D220; DKFZ-Bayer Healthcare Joint Immunotherapeutics Laboratory; Immuntherapie Labor
IDI:(DE-He78)D220-20160331

Recent Publications

All known publications ...
Download: BibTeX | EndNote XML,  Text | RIS | 

http://join2-wiki.gsi.de/foswiki/pub/Main/Artwork/join2_logo100x88.png Journal Article  ;  ;  ;  ;  ;  ;  ;  ;  ;  ;  ;  ;  ;  ;  ;  ;
Discovery of BAY-405: An Azaindole-Based MAP4K1 Inhibitor for the Enhancement of T-Cell Immunity against Cancer
Journal of medicinal chemistry 67(19), 17429-17453 () [10.1021/acs.jmedchem.4c01325]  GO OpenAccess  Download fulltext Files BibTeX | EndNote: XML, Text | RIS

http://join2-wiki.gsi.de/foswiki/pub/Main/Artwork/join2_logo100x88.png Journal Article  ;  ;  ;  ;  ;  ;  ;  ;  ;  ;  ;  ;  ;  ;  ;  ;  ;  ;
Pericyte phenotype switching alleviates immunosuppression and sensitizes vascularized tumors to immunotherapy in preclinical models.
The journal of clinical investigation 134(18), e179860 () [10.1172/JCI179860]  GO DBCoverage BibTeX | EndNote: XML, Text | RIS

http://join2-wiki.gsi.de/foswiki/pub/Main/Artwork/join2_logo100x88.png Journal Article  ;  ;  ;  ;  ;  ;  ;  ;  ;  ;  ;  ;  ;  ;  ;  ;  ;  ;  ;  ;
MHC class II-restricted antigen presentation is required to prevent dysfunction of cytotoxic T cells by blood-borne myeloids in brain tumors.
Cancer cell 41(2), 235-251.e9 () [10.1016/j.ccell.2022.12.007]  GO BibTeX | EndNote: XML, Text | RIS

http://join2-wiki.gsi.de/foswiki/pub/Main/Artwork/join2_logo100x88.png Journal Article  ;  ;  ;  ;  ;  ;  ;  ;  ;  ;  ;  ;  ;  ;  ;  ;  ;  ;  ;  ;  ;  ;  ;  ;  ;  ;  ;  ;  ;  ;
Targeting the aryl hydrocarbon receptor (AhR) with BAY 2416964: a selective small molecule inhibitor for cancer immunotherapy.
Journal for ImmunoTherapy of Cancer 11(11), e007495 () [10.1136/jitc-2023-007495]  GO DBCoverage BibTeX | EndNote: XML, Text | RIS

http://join2-wiki.gsi.de/foswiki/pub/Main/Artwork/join2_logo100x88.png Journal Article (Letter)  ;  ;  ;  ;  ;  ;  ;  ;  ;  ;  ;  ;  ;  ;
Secretogranin II influences the assembly and function of MHC class I in melanoma.
Experimental hematology & oncology 12(1), 29 () [DOI: 10.1186/s40164-023-00387-1]  GO DBCoverage   Download fulltextFulltext by Pubmed Central BibTeX | EndNote: XML, Text | RIS

http://join2-wiki.gsi.de/foswiki/pub/Main/Artwork/join2_logo100x88.png Journal Article  ;  ;  ;  ;  ;  ;  ;  ;  ;  ;  ;  ;  ;  ;  ;  ;  ;  ;  ;  ;  ;  ;  ;  ;  ;
Rgs16 promotes antitumor CD8+ T cell exhaustion.
Science immunology 7(71), eabh1873 () [10.1126/sciimmunol.abh1873]  GO BibTeX | EndNote: XML, Text | RIS

http://join2-wiki.gsi.de/foswiki/pub/Main/Artwork/join2_logo100x88.png Journal Article (Review Article)  ;  ;
Keep a Little Fire Burning—The Delicate Balance of Targeting Sphingosine-1-Phosphate in Cancer Immunity
International journal of molecular sciences 23(3), 1289 () [10.3390/ijms23031289]  GO DBCoverage BibTeX | EndNote: XML, Text | RIS

http://join2-wiki.gsi.de/foswiki/pub/Main/Artwork/join2_logo100x88.png Journal Article  ;  ;  ;  ;  ;  ;  ;  ;  ;  ;  ;  ;  ;  ;  ;  ;  ;  ;  ;  ;  ;  ;  ;  ;  ;  ;  ;  ;  ;  ;
T cell-mediated elimination of cancer cells by blocking CEACAM6–CEACAM1 interaction
OncoImmunology 11(1), 2008110 () [10.1080/2162402X.2021.2008110]  GO DBCoverage BibTeX | EndNote: XML, Text | RIS

http://join2-wiki.gsi.de/foswiki/pub/Main/Artwork/join2_logo100x88.png Journal Article  ;  ;  ;  ;  ;  ;  ;  ;  ;  ;  ;  ;  ;  ;
Proimmunogenic impact of MEK inhibition synergizes with agonist anti-CD40 immunostimulatory antibodies in tumor therapy.
Nature Communications 11(1), 2176 () [10.1038/s41467-020-15979-2]  GO DBCoverage BibTeX | EndNote: XML, Text | RIS

http://join2-wiki.gsi.de/foswiki/pub/Main/Artwork/join2_logo100x88.png Journal Article  ;  ;  ;  ;  ;  ;  ;  ;  ;
Dectin-1 binding to annexins on apoptotic cells induces peripheral immune tolerance via NADPH oxidase-2.
Cell reports 29(13), 4435-4446.e9 ()  GO DBCoverage BibTeX | EndNote: XML, Text | RIS

All known publications ...
Download: BibTeX | EndNote XML,  Text | RIS | 


 Record created 2019-07-05, last modified 2022-03-18



Rate this document:

Rate this document:
1
2
3
 
(Not yet reviewed)